Cargando…

Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression

Introduction: Osteosarcoma (OS), the primary malignant bone tumor, has a low survival rate for recurrent patients. Latest reports indicated that cancer-associated fibroblasts (CAFs) were the main component of tumor microenvironment, and would generate a variable role in the progression of tumors. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhihao, Zhang, Cheng, Ju, Xiaoshuang, Zuo, Yangguang, Ma, Tingyu, Wu, Yongyong, Yang, Zhou, Yao, Jie, Zhou, Tao, Zhang, Xueyu, Hu, Zhe, Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333483/
https://www.ncbi.nlm.nih.gov/pubmed/37441535
http://dx.doi.org/10.3389/fphar.2023.1136960
_version_ 1785070665415524352
author Zhihao, Zhang
Cheng, Ju
Xiaoshuang, Zuo
Yangguang, Ma
Tingyu, Wu
Yongyong, Yang
Zhou, Yao
Jie, Zhou
Tao, Zhang
Xueyu, Hu
Zhe, Wang
author_facet Zhihao, Zhang
Cheng, Ju
Xiaoshuang, Zuo
Yangguang, Ma
Tingyu, Wu
Yongyong, Yang
Zhou, Yao
Jie, Zhou
Tao, Zhang
Xueyu, Hu
Zhe, Wang
author_sort Zhihao, Zhang
collection PubMed
description Introduction: Osteosarcoma (OS), the primary malignant bone tumor, has a low survival rate for recurrent patients. Latest reports indicated that cancer-associated fibroblasts (CAFs) were the main component of tumor microenvironment, and would generate a variable role in the progression of tumors. However, the role of CAFs is still few known in osteosarcoma. Methods: The processed RNA-seq data and the corresponding clinical and molecular information were retrieved from the Cancer Genome Atlas Program (TCGA) database and processed data of tumor tissue was obtained from Gene Expression Omnibus (GEO) database. Xcell method was used in data processing, and Gene set variation analysis (GSVA) was used to calculates enrichment scores. Nomogram was constructed to evaluate prognostic power of the predictive model. And the construction of risk scores and assessment of prognostic predictive were based on the LASSO model. Results: This study classified Cancer Genome Atlas (TCGA) cohort into high and low CAFs infiltrate phenotype with different CAFs infiltration enrichment scores. Then TOP 9 genes were screened as prognostic signatures among 2,488 differentially expressed genes between the two groups. Key prognostic molecules were CGREF1, CORT and RHBDL2 and the risk score formula is: Risk-score = CGREF1*0.004 + CORT*0.004 + RHBDL2*0.002. The signatures were validated to be independent prognostic factors to predict tumor prognosis with single-factor COX and multi-factor COX regression analyses and Norton chart. The risk score expression of risk score model genes could predict the drug resistance, and significant differences could be found between the high and low scoring groups for 17-AAG, AZD6244, PD-0325901 and Sorafenib. Discussion: To sum up, this article validated the prediction role of CAF infiltration in the prognosis of OS, which might shed light on the treatment of OS.
format Online
Article
Text
id pubmed-10333483
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103334832023-07-12 Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression Zhihao, Zhang Cheng, Ju Xiaoshuang, Zuo Yangguang, Ma Tingyu, Wu Yongyong, Yang Zhou, Yao Jie, Zhou Tao, Zhang Xueyu, Hu Zhe, Wang Front Pharmacol Pharmacology Introduction: Osteosarcoma (OS), the primary malignant bone tumor, has a low survival rate for recurrent patients. Latest reports indicated that cancer-associated fibroblasts (CAFs) were the main component of tumor microenvironment, and would generate a variable role in the progression of tumors. However, the role of CAFs is still few known in osteosarcoma. Methods: The processed RNA-seq data and the corresponding clinical and molecular information were retrieved from the Cancer Genome Atlas Program (TCGA) database and processed data of tumor tissue was obtained from Gene Expression Omnibus (GEO) database. Xcell method was used in data processing, and Gene set variation analysis (GSVA) was used to calculates enrichment scores. Nomogram was constructed to evaluate prognostic power of the predictive model. And the construction of risk scores and assessment of prognostic predictive were based on the LASSO model. Results: This study classified Cancer Genome Atlas (TCGA) cohort into high and low CAFs infiltrate phenotype with different CAFs infiltration enrichment scores. Then TOP 9 genes were screened as prognostic signatures among 2,488 differentially expressed genes between the two groups. Key prognostic molecules were CGREF1, CORT and RHBDL2 and the risk score formula is: Risk-score = CGREF1*0.004 + CORT*0.004 + RHBDL2*0.002. The signatures were validated to be independent prognostic factors to predict tumor prognosis with single-factor COX and multi-factor COX regression analyses and Norton chart. The risk score expression of risk score model genes could predict the drug resistance, and significant differences could be found between the high and low scoring groups for 17-AAG, AZD6244, PD-0325901 and Sorafenib. Discussion: To sum up, this article validated the prediction role of CAF infiltration in the prognosis of OS, which might shed light on the treatment of OS. Frontiers Media S.A. 2023-06-27 /pmc/articles/PMC10333483/ /pubmed/37441535 http://dx.doi.org/10.3389/fphar.2023.1136960 Text en Copyright © 2023 Zhihao, Cheng, Xiaoshuang, Yangguang, Tingyu, Yongyong, Zhou, Jie, Tao, Xueyu and Zhe. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhihao, Zhang
Cheng, Ju
Xiaoshuang, Zuo
Yangguang, Ma
Tingyu, Wu
Yongyong, Yang
Zhou, Yao
Jie, Zhou
Tao, Zhang
Xueyu, Hu
Zhe, Wang
Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
title Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
title_full Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
title_fullStr Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
title_full_unstemmed Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
title_short Cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
title_sort cancer-associated fibroblast infiltration in osteosarcoma: the discrepancy in subtypes pathways and immunosuppression
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333483/
https://www.ncbi.nlm.nih.gov/pubmed/37441535
http://dx.doi.org/10.3389/fphar.2023.1136960
work_keys_str_mv AT zhihaozhang cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT chengju cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT xiaoshuangzuo cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT yangguangma cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT tingyuwu cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT yongyongyang cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT zhouyao cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT jiezhou cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT taozhang cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT xueyuhu cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression
AT zhewang cancerassociatedfibroblastinfiltrationinosteosarcomathediscrepancyinsubtypespathwaysandimmunosuppression